



**OFFICIAL MINUTES OF THE MARCH 2, 2020  
MEETING OF THE STATE OF OHIO BOARD OF PHARMACY, HEALTH CLAIMS REVIEW  
COMMITTEE**

**10:13 a.m.** The Health Claims Review Committee convened in room 1924, 19<sup>th</sup> Floor, Vern Riffe Center for Government & the Arts, 77 South High Street, Columbus, Ohio, with the following committee members present:

Bridget Protus, PharmD, MLIS, BCGP, CDP, Krissy Reinstatler, PharmD, BCPP, Jan Scaglione, M.T., PharmD, D.ABAT, GERALYN Waters, PharmD, BCPS, and Harrison Weed, M.D..

Stephanie Abel, PharmD, BCPS and Kathy Burns, MS, APRN-CNS, AGCNS-BC were **Absent**

Also present were Christopher H. Logsdon, *Manager of the Medical Marijuana*, Stephen Wilson, *Medical Marijuana Licensee Liaison*, and Diana Wynkoop, *Ohio Department of Commerce*.

**Agenda item #1: Roll Call**

Dr. Protus took the roll call; noting a quorum of the members were present, she opened the committee meeting to consider regular business. Dr. Protus asked staff to present the first agenda item.

*Material Reviewed: (1) Meeting agenda, (2) Previous Meeting Minutes for December 30, 2019, and (3) Health Claims Crosswalk slide presentation for health claim #1488 submitted by "GTI, Inc." dispensary, including copy of the proposed submission, and health claims references.*

**Agenda item #2: Approval of Prior Meeting Minutes**

**10:15 a.m.** Dr. Protus noted that members had been provided the previous meeting minutes for December 30, 2019. Dr. Protus asked if there was a motion to waive the reading of the minutes.

**R-2020-007** Dr. Reinstatler moved to waive the reading of the December 30, 2019 minutes and to approve the December 30, 2019 meeting minutes of the Health Claims Review Committee. Dr. Weed seconded the motion. Discussion: None. Motion carried: Yes – 5/ No - 0.

**Agenda item #3: Submission #1488: GTI, Inc.**

**10:10 a.m.** Review and Recommendations for Health Claims – Submission #1488: GTI, Inc.

Mr. Logsdon reviewed the decision grid spreadsheet created to document the Committee's discussion and review determinations.

Dr. Protus asked the staff to present the health claim submission for item Submission #1488: GTI, Inc.

*Material Reviewed: Health Claims Crosswalk slide presentation for health claim #1488 submitted by "GTI, Inc." dispensary, including copy of the proposed GTI, Inc.*



*submission: Cover letter, copy of PowerPoint presentation titled "Medical Cannabis in Patients with Alzheimer's Disease." References and location of pin cites – December 23, 2016: Cannabidiol Modulates the Expression of Alzheimer's Disease-Related Genes in Mesenchymal Stem Cells (1 pg), "CB2 Receptor and Amyloid Pathology in Frontal Cortex of Alzheimer's Disease Patients.", Neurobiol Aging. 2013 Mar;34(3): 805-8 (1 pg provided), Cannabinoid CB<sub>2</sub> receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains.: J Neurosci 2003;23;11136-11141 (1 pg provided), the activation of cannabinoid CB<sub>2</sub> receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages. Brain Research 1283 (2009) 148-154 (1 pg provided), Activation of the CB<sub>2</sub> receptor system reverses amyloid-induced memory deficiency. Neurobiol of Aging 34 (2013) 719-804 (1 pg provided), Cannabinoids as antioxidants and neuroprotectants, U.S. Patent, Oct. 7, 2003 (1 pg provided), Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on  $\beta$ -amyloid-induced toxicity in PC12 cells. J. Neurochem. (2004) 89, 134-141 (1 pg provided), A Molecular Link Between the Active Component of Marijuana and Alzheimer's Disease Pathology. Mol Pharm. 2006; 3(6):773-777 (1 pg provided), Terpenes, Phenylpropanoids, Sulfur and Other Essential Oil Constituents as Inhibitors of Cholinesterases. Curr Med Chem. 2018; 10.2174 (1 pg provided), Effects of dronabinol in anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 1997; 12(9):913-9 (1 pg provided), Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia; Psychopharmacology. (2006) 185: 524-528 (2 pgs provided), and Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study. J Alzheimers Dis. 2016;51(1): 15-9 (1 pg provided).*

Mr. Wilson reviewed the Health Claims Crosswalk presentation, which contained each Health Claim and pin cite references to provided materials. Members reviewed and discussed each claim and the decisions/recommendations were documented. Following discussion, the members reviewed the decisions and recommendations made by the Committee for each identified claim in Submission #1488: GTI, Inc.

**R-2020-008** Dr. Weed moved to approve the decisions and recommendations of the Health Claims Review Committee for submission #1488: GTI, Inc. as read (attached hereto as Exhibit A titled, "Health Claims Review Committee Decision Grid #1488 GTI, Inc."). Dr. Scaglione seconded the motion. Discussion: None. Motion carried: Yes –5/ No - 0.

#### **Agenda item #4: Next Meeting Date - discussion**

**12:15 p.m.** Dr. Protus then opened discussion concerning the next meeting date for the Health Claims Review Committee meeting. After some discussion, the recommendation was made to determine if members could be available on April 15, 2020 and send out notification to the Committee Members if acceptable.

#### **Agenda item #5: Adjourn**

**12:23 p.m.** Dr. Protus entertained a motion to adjourn.


**R-2020-009** Dr. Reinstatler moved to adjourn. Dr. Waters seconded the motion. Discussion: None. Motion carried: Yes –5/ No - 0.



STATE OF  
**OHIO**  
BOARD OF PHARMACY



12:23 p.m. The meeting adjourned.

  
Bridget Protus, PharmD, MLIS, BCGP, CDP

Date:

6/3/2020



**12:23 p.m.** The meeting adjourned.

\_\_\_\_\_  
Bridget Protus, PharmD, MLIS, BCGP, CDP

Date: \_\_\_\_\_